Loading…
← CockpitCompetitor Analysis › 002788.SZ Luyan Pharma Co., Ltd. Class AOpen in the cockpit ↗

Luyan Pharma Co., Ltd. Class A002788.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Drugstore Chains
Momentum weak 30
Mkt cap
$514M
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$13.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.3 pp
WACC 5.0%
Hurdle
-7 pp
Req g minus delivered
Close · CNYCN¥8.92
1D-0.9%
1W-7.6%
1M-10.0%
3M-24.0%
6M-32.5%
YTD-57.9%
1Y+2.2%
ATR %3.8%
52w lowhigh68.5% off high

What Luyan Pharma does

Employees: 5,722

Luyan Pharma at a glance

Size Luyan Pharma (002788.SZ) is a China Consumer Staples company (Drugstore Chains) with a market value of $514M, the 3629th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.92 on 18 Nov 2026.

Performance Over six months the shares fell 32.5%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 15 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +6.5%); the operating margin is 2.6% (peer median 4.3%).

Valuation It trades at 0.4× enterprise value to sales against a peer median of 0.8× (4th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.3 points above its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 95002788.SZ 69
Six months, rebased to 100: Luyan Pharma against the median of its 14 peers (local-currency closes).

Luyan Pharma financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥21.6BCN¥21.2BCN¥20.4BCN¥19.8BCN¥19.4B
Revenue growth—+4%+3%+2%—
Gross profitCN¥1.50BCN¥1.34BCN¥1.37BCN¥1.36BCN¥1.37B
EBITDAn/aCN¥720MCN¥821MCN¥823MCN¥809M
Net incomeCN¥274MCN¥281MCN¥346MCN¥364MCN¥345M
Free cash flowCN¥307MCN¥455MCN¥216MCN¥780M-CN¥95.3M
Capital expenditureCN¥185MCN¥234MCN¥361MCN¥529MCN¥328M
Total debtCN¥6.61BCN¥6.96BCN¥6.58BCN¥5.95BCN¥6.05B

Quarterly statements and history in the cockpit →

Luyan Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%603590303426643010179267301408000504MEDPLUS6008336052660027279627603883002788.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Luyan Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×2×4×60359030342664301017301408000504600833002727002788.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Luyan Pharma is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%60359030342664301017301408MEDPLUS60083360526600272796273148603883002788.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Luyan Pharma is the large dot.

Luyan Pharma competitors and peer comparison

How Luyan Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Luyan Pharma against its 14 peers (data as of 18 Nov 2026)
Measure002788.SZPeer medianRank in peer set
1-month return-10.0%-1.0%7th lowest of 15
6-month return-32.5%-4.5%4th lowest of 15
Distance from 52-week high-68.5%-35.5%lowest of 15
Revenue growth (TTM)+3.1%+6.5%7th lowest of 15
Operating margin2.6%4.3%6th lowest of 15
EV / Sales0.4×0.8×4th cheapest of 15
Growth the price implies (Req g, 7 yrs)-0.4%-7.0%5th most demanding of 13
Growth delivered (Del g)+6.5%+11.1%4th lowest of 13
Hurdle (Req g minus delivered)-6.8 pp-20.0 pp5th most demanding of 13
ROIC minus cost of capital+0.3 pp+2.6 pp6th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Luyan Pharma 002788.SZChina$514M-32%+3%3%0.4×-0.4%+6.5%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%4.2×12.4%+2.7%
Qol 3034.TJapan$561M+26%+5%6%0.4×-16.6%+12.4%
Cawachi 2664.TJapan$562M+31%-1%2%0.2×-6.1%0.0%
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%0.8×1.1%+17.4%
Genky DrugStores 9267.TJapan$728M+3%+8%5%0.6×n/an/a
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%1.1×-7.5%+23.3%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%3.1×n/an/a
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%1.1×18.6%+17.6%
Shanghai No. 1 Pharmacy 600833.SSChina$299M-22%+1%-1%0.9×19.5%+6.1%
JZJ Chain Drugstore Corporation 605266.SSChina$293M-35%-5%0%0.7×-9.9%+14.8%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%0.5×-16.0%+6.5%
Ain 9627.TJapan$1.25B+2%+42%4%0.5×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%0.3×-11.5%+8.0%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%0.8×-10.7%+9.7%

Questions

Which companies are Luyan Pharma's closest peers?
The cockpit's peer set: Beijing Konruns Pharmaceutical (603590.SS), Qol (3034.T), Cawachi (2664.T), Shu Yu Civilian Pharmacy (301017.SZ), Genky DrugStores (9267.T), Anhui Huaren Health Pharmaceutical (301408.SZ), Landfar Bio-medicine (000504.SZ), MedPlus Health Services (MEDPLUS.NS).
Is Luyan Pharma expensive compared with its peers?
On ev / sales it trades at 0.4× against a peer median of 0.8×, 4th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Luyan Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -32.5% against -4.5% for the median peer; over one year +2.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.